Long-term follow-up after successful interferon therapy of acute hepatitis C
Open Access
- 30 June 2004
- journal article
- viral hepatitis
- Published by Wolters Kluwer Health in Hepatology
- Vol. 40 (1) , 98-107
- https://doi.org/10.1002/hep.20291
Abstract
Early treatment of acute hepatitis C infection with interferon alfa-2b (IFN-α-2b) prevents chronicity in almost all patients. So far, no data are available on the long-term outcome after interferon (IFN) therapy of acute hepatitis C. The aim of this study was to assess the clinical, virological, and immunological long-term outcome of 31 successfully treated patients with acute hepatitis C infection who were followed for a median of 135 weeks (52-224 weeks) after end of therapy. None of the individuals had clinical evidence of liver disease. Alanine aminotransferase (ALT) levels were normal in all but 1 patient. Serum hepatitis C virus (HCV) RNA was negative throughout follow-up, even when investigated with the highly sensitive transcription-mediated amplification (TMA) assay (cutoff 5-10 IU/mL). In addition, no HCV RNA was detected in peripheral blood mononuclear cells (PBMC) of 15 cases tested. The patients’ overall quality-of-life scores as determined by the SF-36 questionnaire did not differ from the German reference control cohort. Ex vivo interferon gamma (IFN-γ) ELISPOT analysis detected HCV-specific CD4+ T-helper cell reactivity in only 35% of cases, whereas HCV-specific CD8+ T-cell responses were found in 4 of 5 HLA-A2-positive individuals. Anti-HCV antibody levels decreased significantly during and after therapy in all individuals. In conclusion, early treatment of symptomatic acute hepatitis C with IFN-α-2b leads to a long-term virological, biochemical, and clinical response. Waning of anti-HCV humoral immunity and presence of HCV-specific CD8+ (but not CD4+) T cells highlights the complexity of T-cell and B-cell memory to HCV, which might be significantly altered by IFN treatment. (Hepatology 2004;40:98-107.)Keywords
Funding Information
- German Network of Competence on Viral Hepatitis (“Hep-Net”; project 10.2.2)
- BMBF (German Ministry for Science and Education)
- Essex Pharma (Munich, Germany)
This publication has 43 references indexed in Scilit:
- Whom? When? How? Another piece of evidence for early treatment of acute hepatitis CHepatology, 2004
- HCV Persistence and Immune Evasion in the Absence of Memory T Cell HelpScience, 2003
- Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance1 1The Bundesministerium für Bildung und Forschung and the European Union, as sponsors of the study, had no role in study design, data collection, analysis, or interpretation or in the writing and the decision to submit the report for publication.Gastroenterology, 2003
- Prediction of Spontaneous Viral Clearance in Acute Hepatitis C by Viral Load MeasurementsHepatology, 2003
- Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral loadHepatology, 2003
- Treatment of Acute Hepatitis C with Interferon Alfa-2bNew England Journal of Medicine, 2001
- Association of Hepatitis C Virus–Specific CD8+T Cells with Viral Clearance in Acute Hepatitis CThe Journal of Infectious Diseases, 2000
- Mutational pattern of hepatitis B virus on sequential therapy with famciclovir and lamivudine in patients with hepatitis B virus reinfection occurring under hbig immunoglobulin after liver transplantationHepatology, 1999
- Enlargement of perihepatic lymph nodes in relation to liver histology and viremia in patients with chronic hepatitis CHepatology, 1997
- Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virusHepatology, 1997